Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second-look laparotomy

J L Moore1, J F Barter

  • 1Lombardi Cancer Research Center, Department of Obstetrics and Gynecology, Georgetown University Medical Center, Washington, DC 20007.

Seminars in Surgical Oncology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive factors for prolonged nutritional support after oesophagogastric cancer resection.

Annals of the Royal College of Surgeons of England·2026
Same author

Clinical Relevance of the Tumor Location-Modified Laurén Classification System for Gastric Cancer in a Western Population.

Annals of surgical oncology·2022
Same author

Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis.

Science (New York, N.Y.)·2021
Same author

Cost estimation alongside a multi-regional, multi-country randomized trial of antenatal ultrasound in five low-and-middle-income countries.

BMC public health·2021
Same author

Association of haemoglobin levels in the first trimester and at 26-30 weeks with fetal and neonatal outcomes: a secondary analysis of the Global Network for Women's and Children's Health's ASPIRIN Trial.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Author Correction: Nutrients cause grassland biomass to outpace herbivory.

Nature communications·2021
Same journal

Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment.

Seminars in surgical oncology·2003
Same journal

Preoperative chemoradiation for locally advanced rectal adenocarcinoma-the University of Florida experience.

Seminars in surgical oncology·2003
Same journal

Postoperative adjuvant therapy for pancreatic cancer.

Seminars in surgical oncology·2003
Same journal

Conformal chemoradiation for primary and metastatic liver malignancies.

Seminars in surgical oncology·2003
Same journal

Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.

Seminars in surgical oncology·2003
Same journal

Combined modality therapy in esophageal cancer: the Memorial experience.

Seminars in surgical oncology·2003
See all related articles

Second-look laparotomy is crucial for assessing ovarian cancer treatment response by detecting residual disease. Despite limitations, it remains the gold standard for evaluating treatment effectiveness in ovarian cancer patients.

Area of Science:

  • Gynecologic Oncology
  • Surgical Oncology

Background:

  • Second-look laparotomy (SLL) is vital for evaluating treatment response in ovarian cancer.
  • It aids in detecting minimal residual disease missed by other methods.

Purpose of the Study:

  • To highlight the role of SLL in assessing therapeutic response in ovarian cancer.
  • To discuss its controversial yet gold standard status in disease detection post-chemotherapy.

Main Methods:

  • Surgical exploration to identify persistent or recurrent ovarian cancer.
  • Biopsy and pathological examination of suspicious lesions.

Main Results:

  • SLL can detect small-volume disease not evident through less invasive assessments.
  • A significant proportion of patients with negative SLL findings may still experience disease recurrence.

Related Experiment Videos

Conclusions:

  • Second-look laparotomy is essential for precise staging and treatment planning in ovarian cancer.
  • Its utility is debated due to recurrence rates in some patients, but it remains the benchmark for assessing chemotherapy response.